Given the CV benefit noted in the CVOTs, GLP-1RAs and SGLT-2is are given preference in T2DM guidelines. While guidelines do not report potential gender difference, those differences exist. On restricting the CVOTs results to women with increased CV risk or established ASCVD, GLP-1RAs significantly reduced MACE while SGLT-2is resulted in a non-significant reduction.
Keywords: CVOT; GLP-1 receptor agonist; SGLT-2 inhibitors; Type 2 diabetes; Women.
Copyright © 2022 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.